Microtumor-induced vascular development

March 13, 2002

Solid tumors above a critical size become hypoxic at their core. The upregulation of the angiogenic factor VEGF under these conditions is widely thought to explain tumor vascularization and continued proliferation, but Vajkoczy and coworkers point out that some metastatic tumor cells express low levels of bio-active VEGF in a constitutive manner and appear to require VEGF signaling even at a very early stage. These authors used intravital microsopy to show that glioma cells interact with the host vasculature and begin to induce angiogenesis at times well before the tumor mass has reached this limit. Small cell clusters or individual glioma cells, implanted in a vascularized tissue, spread along existing vessels. The resulting tumors did not appear to grow around the existing vessels, as would have been predicted by the so-called "cooptation" model. Rather, infiltrating cells that broke from a tumor mass appeared to migrate along these vessels and induce the sprouting of new ones, which could be distinguished from normal vessels by their disorganized structure and their leakiness. Evidently, at least for this VEGF+ tumor cell type, vascular outgrowth does not begin with hypoxia, but occurs as a continuing process of growth and remodeling, starting early in tumor progression.

JCI Journals

Related Angiogenic Factor Vegf Articles from Brightsurf:

Sleep apnea may be risk factor for COVID-19
The question of sleep apnea as the risk factor for COVID-19 arose in a study conducted by the Turku University Hospital and the University of Turku on patients of the first wave of the pandemic.

A factor limiting recovery from bleaching in corals
A joint research team has examined the effect of pre-exposure to heat stress on the capacity of symbiotic algae to infect cnidarian hosts using the Aiptasia (sea-anemone)-zooxanthellae (algae) model system.

St18 is a negative regulator of VEGF
A research team led by Kenta Maruyama M.D., Ph.D. from National Institute for Physiological Sciences explored the role of St18 in the regulation of VEGF expression.

Tracking cancer's immortality factor
Canadian researchers discover how a key cancer mutation activates telomerase, the 'anti-aging enzyme' that makes tumour cells immortal.

Acoustic growth factor patterning
For optimally engineered tissues, it is important that biological cues are delivered with appropriate timing and to specific locations.

The sleeping Sigma-Factor
previously unknown mechanism enables bacterial antibiotic resistance

Identification of signature genes associated with therapeutic resistance to anti-VEGF therapy
To establish a molecular signature of this resistance in ovarian cancer, the authors developed preclinical tumor models of adaptive resistance to chronic anti-VEGF treatment.

Combination of immunotherapy and VEGF inhibitor improves survival in HCC
Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC) compared to standard of care, showed results from a phase 3 study to be reported at the ESMO Asia 2019 Congress.

Discovery of a restriction factor for hepatitis B virus
Hepatitis B is a viral liver infection that can lead to acute or chronic conditions.

New regulatory factor identified in bone formation
Researchers report the identification of a novel transcription factor that helps regulate the differentiation of mesenchymal stem cells into bone in mice.

Read More: Angiogenic Factor Vegf News and Angiogenic Factor Vegf Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.